These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 11498597)

  • 1. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Ruth TJ; Sossi V; Schulzer M; Calne DB; Stoessl AJ
    Science; 2001 Aug; 293(5532):1164-6. PubMed ID: 11498597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of expectation on placebo-induced dopamine release in Parkinson disease.
    Lidstone SC; Schulzer M; Dinelle K; Mak E; Sossi V; Ruth TJ; de la Fuente-Fernández R; Phillips AG; Stoessl AJ
    Arch Gen Psychiatry; 2010 Aug; 67(8):857-65. PubMed ID: 20679593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine release in human ventral striatum and expectation of reward.
    de la Fuente-Fernández R; Phillips AG; Zamburlini M; Sossi V; Calne DB; Ruth TJ; Stoessl AJ
    Behav Brain Res; 2002 Nov; 136(2):359-63. PubMed ID: 12429397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study.
    Ouchi Y; Yoshikawa E; Futatsubashi M; Okada H; Torizuka T; Sakamoto M
    J Cereb Blood Flow Metab; 2002 Jun; 22(6):746-52. PubMed ID: 12045673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competition between 11C-raclopride and endogenous dopamine in Parkinson's disease.
    Ishibashi K; Ishii K; Oda K; Mizusawa H; Ishiwata K
    Nucl Med Commun; 2010 Feb; 31(2):159-66. PubMed ID: 19966595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition.
    de La Fuente-Fernández R; Lim AS; Sossi V; Holden JE; Calne DB; Ruth TJ; Stoessl AJ
    J Cereb Blood Flow Metab; 2001 Oct; 21(10):1151-9. PubMed ID: 11598492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Placebo effect in Parkinson's disease].
    Miwa H
    No To Shinkei; 2007 Feb; 59(2):139-46. PubMed ID: 17315755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo effect and dopamine release.
    de la Fuente-Fernández R; Lidstone S; Stoessl AJ
    J Neural Transm Suppl; 2006; (70):415-8. PubMed ID: 17017561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Stoessl AJ
    Trends Neurosci; 2002 Jun; 25(6):302-6. PubMed ID: 12086748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.
    Piccini P; Brooks DJ; Björklund A; Gunn RN; Grasby PM; Rimoldi O; Brundin P; Hagell P; Rehncrona S; Widner H; Lindvall O
    Nat Neurosci; 1999 Dec; 2(12):1137-40. PubMed ID: 10570493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
    Piccini P; Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.
    Rinne UK; Laihinen A; Rinne JO; Någren K; Bergman J; Ruotsalainen U
    Mov Disord; 1990; 5(1):55-9. PubMed ID: 2136932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.